The number of individuals diagnosed with type II diabetes, which is caused by the ‘metabolic syndrome’ – obesity, insulin resistance and/or abnormal insulin secretion, is increasing worldwide, and creating a strong demand for the development of more effective anti-diabetic drugs [1]. The gene discussed is INS; the disease is type 2 diabetes mellitus.